A study of Eli Lilly and Amylin Pharmaceuticals’ experimental diabetes drug just fell short.
The study failed to show that Bydureon, a once-a-week diabetes shot, was as effective at lowering blood sugar as Victoza, a once-a-day drug from Novo Nordisk.
That result led to new doubts about Bydureon, which many analysts forecast could have sales of more than $1 billion but which is already facing a delay at the Food and Drug Administration.
via blogs.forbes.com
No comments:
Post a Comment